Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The 4 mg dose of baricitinib, but not the 2 mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy. The safety profile observed was consistent with previous studies of baricitinib.
This study lays the groundwork for future phase 3 trials, exploring JAK1/2 inhibition with baricitinib as a promising new oral therapy for systemic lupus erythematosus.
…